Literature DB >> 1979207

Absence of central effects with levocabastine eye drops.

F Arriaga1, N Rombaut.   

Abstract

Twelve healthy volunteers were randomly allocated to receiving in a double-blind cross-over fashion levocabastine eye drops (0.5 mg/ml solution) and placebo. They were advised to instill 2 drops per eye, four times daily. Each treatment was administered for a period of 1 week. Before and after each treatment period psychomotor function was assessed using Critical Flicker Fusion Test and the Choice Reaction Time Test. At the same time intervals a subjective evaluation of sedation was given using a Visual Analogue of Sedation. Both objective and subjective measurements showed that no significant treatment effects could be detected. It is concluded that repeated instillations of levocabastine eye drops are devoid of any sedative side effects.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1979207     DOI: 10.1111/j.1398-9995.1990.tb00531.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  6 in total

Review 1.  Safety and tolerability profiles of intranasal antihistamines and intranasal corticosteroids in the treatment of allergic rhinitis.

Authors:  Rami Jean Salib; Peter Hugo Howarth
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 2.  The antihistamines of the nineties.

Authors:  M M Janssens; P H Howarth
Journal:  Clin Rev Allergy       Date:  1993

Review 3.  Levocabastine. A review of its pharmacological properties and therapeutic potential as a topical antihistamine in allergic rhinitis and conjunctivitis.

Authors:  K L Dechant; K L Goa
Journal:  Drugs       Date:  1991-02       Impact factor: 9.546

Review 4.  Ocular allergy guidelines: a practical treatment algorithm.

Authors:  Leonard Bielory
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 5.  H1-receptor antagonists. Comparative tolerability and safety.

Authors:  F E Simons
Journal:  Drug Saf       Date:  1994-05       Impact factor: 5.606

6.  A review of the tolerability and safety of levocabastine eye drops and nasal spray. Implications for patient management.

Authors:  P H Howarth
Journal:  Mediators Inflamm       Date:  1995       Impact factor: 4.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.